David Meeker, Rhythm Pharmaceuticals CEO
December 22, 2020 10:17 AM ESTUpdated 10:57 AM
R&D

Rhythm Phar­ma knocked off stride as mixed PhI­II obe­si­ty da­ta for its sole big drug look ‘meh’ to many

John Carroll

Editor & Founder

Just a few weeks af­ter Rhythm Phar­ma­ceu­ti­cals $RYTM snagged an FDA OK for set­melan­otide in 3 rare ge­net­ic dis­or­ders that trig­ger obe­si­ty, the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Can Bill An­der­son save Bay­er?

Drug pol­i­cy vet­er­an at CMS to de­part on Fri­day

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times